Choosing AR-Targeted Therapy in CSPC

Daniel P. Petrylak, MD, discusses the impact of the approval of apalutamide in the metastatic castration-sensitive prostate cancer setting.

Daniel P. Petrylak, MD, discusses the design and results of the TITAN trial of apalutamide in patients with metastatic castration-sensitive prostate cancer.

During a live virtual event, Daniel C. Danila, MD, discussed how to treat a patient with de novo metastatic castration-sensitive prostate cancer and monitor for disease progression.

During a live virtual event, Matthew B. Rettig, MD, discussed the guidelines and practical considerations for giving the 4 approved agents for metastatic castration-sensitive prostate cancer.

During a live virtual event, Matthew B. Rettig, MD, discussed the results of the TITAN trial of apalutamide for patients with metastatic castration-sensitive prostate cancer.

During a live virtual event, Roby A. Thomas, MD, discussed the choice of therapy for a patient with metastatic castration-sensitive prostate cancer.

During a live virtual event, Roby A. Thomas, MD, discussed the tolerability of androgen receptor therapy and personal experiences with treatment of patients with metastatic castration-sensitive prostate cancer. This is the second of 2 articles based on this event.